• 1. Aggregation of biologically important peptides and proteins: inhibition or acceleration depending on protein and metal ion concentrations
  Benjamin Gabriel Poulson,Kacper Szczepski,Joanna Izabela Lachowicz,Lukasz Jaremko,Abdul-Hamid Emwas,Mariusz Jaremko RSC Adv., 2020,10, 215-227
• 2. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 3. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 4. An ionic liquid-based synergistic extraction strategy for rare earths?
  Yingbo Li,Nada Mehio,Huizhou Liu,Sheng Dai Green Chem., 2015,17, 2981-2993
• 5. Aggregation of the metallocycles {Cu8} and {Cu20} using [Cu(bp)] units (H2bp = bis(2-hydroxybenzyl)amine): structures and magnetic properties?
  Mei-Yu Xu,Ya-Ting Wang,Qing-Ling Ni,Zi-Hao Zhang,Guang-Ming Liang,Liu-Cheng Gui Dalton Trans., 2016,45, 4993-4997

Introduction to (1S,2R)-Methyl 2-(2-(tert-butoxy)-2-oxoethyl)cyclopropanecarboxylate and Its Significance in Modern Chemical Biology

Chemical compounds play a pivotal role in the advancement of pharmaceutical sciences, particularly in the development of novel therapeutic agents. Among these, (1S,2R)-Methyl 2-(2-(tert-butoxy)-2-oxoethyl)cyclopropanecarboxylate (CAS No. 79252-64-5) stands out due to its unique structural features and promising biological activities. This compound has garnered significant attention in recent years, primarily because of its potential applications in drug discovery and molecular research.

The structure of (1S,2R)-Methyl 2-(2-(tert-butoxy)-2-oxoethyl)cyclopropanecarboxylate is characterized by a cyclopropane ring substituted with a carboxylate group and an ethyl chain terminated by a tert-butoxy moiety. This specific arrangement imparts distinct chemical and biological properties to the molecule, making it a valuable scaffold for medicinal chemistry investigations. The cyclopropane ring, known for its strain and rigidity, often enhances binding affinity to biological targets, while the tert-butoxy group provides steric hindrance and metabolic stability.

In recent years, there has been a surge in research focused on cyclopropane-containing compounds due to their unique pharmacological profiles. Studies have demonstrated that such molecules can exhibit potent activity against various diseases, including cancer, inflammation, and infectious disorders. The (1S,2R) configuration of this compound is particularly noteworthy, as enantioselective synthesis has become increasingly important in drug development. The stereochemistry of the molecule can significantly influence its biological activity, making it a subject of intense interest for chemists and biologists alike.

One of the most compelling aspects of (1S,2R)-Methyl 2-(2-(tert-butoxy)-2-oxoethyl)cyclopropanecarboxylate is its potential as a bioactive scaffold. Researchers have leveraged its structural motifs to design molecules with enhanced efficacy and reduced side effects. For instance, modifications to the cyclopropane ring or the ethyl chain have led to compounds with improved pharmacokinetic properties. These findings underscore the importance of structure-activity relationships (SAR) in optimizing drug candidates.

The tert-butoxy group in this compound plays a crucial role in modulating its reactivity and stability. This protective group is commonly used in organic synthesis to prevent unwanted side reactions and to enhance the compound's shelf life. Additionally, the presence of a carboxylate moiety suggests that this molecule may participate in various biochemical interactions, such as binding to proteins or enzymes. Such interactions are critical for drug action and are often the focus of high-throughput screening campaigns.

Recent advancements in computational chemistry have further illuminated the potential of (1S,2R)-Methyl 2-(2-(tert-butoxy)-2-oxoethyl)cyclopropanecarboxylate as a lead compound. Molecular docking studies have identified its binding affinity to several therapeutic targets, including kinases and transcription factors. These studies not only provide insights into its mechanism of action but also guide future modifications to improve its therapeutic potential. The integration of experimental data with computational predictions has become indispensable in modern drug discovery.

The synthesis of (1S,2R)-Methyl 2-(2-(tert-butoxy)-2-oxoethyl)cyclopropanecarboxylate represents a significant achievement in synthetic organic chemistry. The development of efficient synthetic routes has enabled researchers to produce this compound on a scalable basis, facilitating further biological evaluations. Techniques such as asymmetric hydrogenation and chiral auxiliary-assisted synthesis have been employed to achieve the desired stereochemistry with high enantiomeric purity. These methodologies highlight the progress made in synthetic methodologies over recent decades.

Biological evaluations of this compound have revealed promising activities across multiple disease models. In particular, studies have shown that derivatives of this scaffold exhibit anti-inflammatory properties by modulating cytokine production and immune cell signaling pathways. Such findings align with current trends in drug development towards targeted therapies that address specific disease mechanisms rather than broad-spectrum approaches.

The pharmacokinetic profile of (1S,2R)-Methyl 2-(2-(tert-butoxy)-2-oxoethyl)cyclopropanecarboxylate is another area of active investigation. Understanding how a compound is absorbed, distributed, metabolized, and excreted (ADME) is crucial for determining its clinical efficacy and safety. Preliminary studies suggest that this molecule exhibits favorable pharmacokinetic properties, including good oral bioavailability and moderate metabolic clearance rates. These characteristics make it an attractive candidate for further development into an oral therapeutic agent.

The future prospects for (1S,2R)-Methyl 2-(2-(tert-butoxy)-2-oxoethyl)cyclopropanecarboxylate are vast and multifaceted. Ongoing research aims to explore its potential applications in treating neurological disorders by targeting specific neurotransmitter systems or modulating synaptic plasticity. Additionally,structure-based drug design approaches are being employed to optimize its interactions with biological targets through rational molecular modifications.

In conclusion,(1S,2R)-Methyl 2-(2-(tert-butoxy)-2-oxoethyl)cyclopropanecarboxylate represents a significant advancement in chemical biology with implications for drug discovery across multiple therapeutic areas。 Its unique structural features, stereochemical configuration,and promising biological activities make it a valuable compound for further investigation。 As research continues，this molecule is poised to contribute significantly to the development of novel therapeutics that address unmet medical needs。

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)